Article
A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53.
Proceedings of the National Academy of Sciences of the United States of America - 10 Mar 2009
Sur Surojit, Pagliarini Raymond, Bunz Fred, Rago Carlo, Diaz Luis A, Kinzler Kenneth W, Vogelstein Bert, Papadopoulos Nickolas
Abstract excerpt
Through targeted homologous recombination, we developed a panel of matched colorectal cancer cell lines that differ only with respect to their endogenous TP53 status. We then used these lines to define the genes whose expression was altered after DNA damage induced by ionizing radiation. Transcriptome analyses revealed a consistent up-regulation of polo-like kinase 1 (PLK1) as well as other genes controlling the...
Topics
- Alleles
- Animals
- Antineoplastic Agents
- Cell Line, Tumor
- Cyclin-Dependent Kinase Inhibitor p21
- G1 Phase
- Gene Expression Profiling
- Gene Targeting
- Genotype
- Humans